




Motivation

Distributed Data and Knowledge

- Formats (XML, CSV)
- Notations (Ensembl, HGNC)
- Schemas (molecular_weight, mol-wt)




	PROTEIN		DRUG - ACTIVE
	ENZYME		DRUG - REDUCED EFFECT
	TRANSPORTER		DRUG - INCREASED TOXICITY
	COMPONENT		DRUG - INACTIVE




Integrated Systems Pharmacology

- Discovery of novel drug-adverse reaction associations.
- Mechanism-based prediction of drug safety and toxicity.
- Exploration of the underlying biological mechanisms.




Life Sciences Linked Open Data (LSLOD) Cloud

Kyoto Encyclopedia of Genes and Genomes (KEGG)




Viagra (Mol. Wt.: 666.7, Half-Life: 4 hours) inhibits PDE5, involved in signal transduction.

Resource Description Framework (RDF)



List all drugs that have Mol. Wt < 1000 and inhibit proteins involved in signal transduction. Mention their half-life.


SPARQL Query Language



Reference: <http://lod-cloud.net/>

- Life Sciences Linked Open Data Cloud: 1T+ triples from 80+ biomedical sources.
- Develop Bio-mashups and Linked Biomedical Dataspaces facilitating *in silico* data discovery

Query Federation



DrugBank: Drug
 ❖ molecular-weight < 1000
 ❖ drug-target
 ❖ half-life

KEGG: Drug
 ❖ mol_weight < 1000
 ❖ target
 ❖ process = "GO:0007165"

QUERY FEDERATION

Mapping Rules


Drug
 ❖ molecular-weight < 1000
 ❖ target
 ❖ process = "GO:0007165"
 ❖ half-life

List drugs that have Mol. Wt < 1000 and inhibit proteins involved in signal transduction. Mention their half-life.


Entity Types	Relation Types
E1 Drug	R1 Drug hasTarget Protein
E2 Protein	R2 Drug hasEnzyme Protein
E3 Pathway	R3 Drug hasTransporter Protein
E4 Phenotype	R4 Protein isPresentIn Pathway
	R5 Pathway isImplicatedIn Phenotype

Mapping Rules

R1: Drug hasTarget Protein



Life Sciences Linked Open Data (LSLOD) Cloud



Inputs-Outcomes Database

U.S. FDA Adverse Event Reporting System (FAERS) collects reports on the adverse reactions from multiple drug intake.


Inference Module

Reporting Ratio (Observed/Expected)

2x2 tables for drug-reaction and drug-drug-reaction associations

	ADR _k = Yes	ADR _k = No		ADR _k = Yes	ADR _k = No
Drug _i = Yes	C ₁₁	C ₁₀	Drug _i = Yes & Drug _j = Yes	C ₁₁	C ₁₀
Drug _i = No	C ₀₁	C ₀₀		Drug _i = No Drug _j = No	C ₀₁

Enriching Short Subgraphs with Observed and Expected counts



- Compute shortest subgraphs between drugs and phenotypes.
- Enrich the subgraphs with actual and expected counts.
- Compute association scores



$$w(v_i, v_j) = 1 + \frac{p(v_i \rightarrow v_j | G(C_{obs}))}{p(v_i \rightarrow v_j | G(C_{exp}))}$$

$$p(v_i \rightarrow v_j | G(C_*)) = \frac{\#(v_i \rightarrow v_j)}{\#(v_i \rightarrow \bullet)}$$


"Gold" Standard

Manually curated from known drug-reaction and drug-drug-reaction associations listed under MediSpan, Drugs.com and EU-ADR datasets.

Preliminary Results



Drug - Adverse Reaction Visualizer



Conclusion

- An integrated systems pharmacology-based approach that queries the LSLOD cloud and generates a *k*-partite graph with drug, protein, pathway and phenotype entities.
- Proof-of-concept to discover drug-reaction and drug-drug-reaction associations, and explore the underlying biological mechanisms.
- Inference method can be repurposed using another Inputs-Outcomes data source.
- Similarly, different *k*-partite networks can easily be generated using the query federation client.
- Problems such as data quality, reporting biases, indication biases, patient stratification, interactions due to multiple drugs not dealt.
- We will like to validate discovered mechanisms using PubMed literature, as well as evaluate method using MGPS and BCPNN baselines.

Acknowledgments: Michel Dumontier (Bio2RDF), Erik van Mulligen (EU-ADR), Rainer Winnen (Drug-ADR) This work is supported by grant U54-HG004028 from the US National Institutes of Health.